1. Introduction {#sec1-ijms-17-02015}
===============

Colorectal cancer (CRC) is the third deadliest of all cancers \[[@B1-ijms-17-02015]\]. Nearly one-third of the patients will eventually die of the disease. Targeting the epidermal growth factor receptor (EGFR), an important component in CRC carcinogenesis, is one of the major therapeutic options in metastatic CRC (mCRC). Two anti-EGFR monoclonal antibodies (mAbs), cetuximab and panitumumab, are commonly used in mCRC. Clinical trials have shown the benefit of anti-EGFR mAbs alone or in combination with chemotherapy in mCRC \[[@B2-ijms-17-02015],[@B3-ijms-17-02015],[@B4-ijms-17-02015]\].

Several studies have demonstrated that *KRAS* mutation in exon 2 is a predictive marker of resistance to anti-EGFR mAbs \[[@B5-ijms-17-02015]\]. More recently, other activating *RAS* mutations (*KRAS* exons 3 and 4 and *NRAS* exons 2, 3 and 4) were also shown to confer resistance to anti-EGFR mAbs \[[@B3-ijms-17-02015],[@B4-ijms-17-02015]\]. Approximately 50% of mCRC harbor mutations in exons 2, 3 or 4 of either *KRAS* or *NRAS* genes \[[@B6-ijms-17-02015]\]. The most frequent mutations are detected in exon 2 (codons 12 and 13) of *KRAS* (40%), and, to a lesser extent, in exon 3 (codons 59 and 61) and exon 4 (codons 117 and 146) of *KRAS* (≈7% of cases). Activating mutations of *NRAS* occur only in a subset of mCRC (≈5% of cases), mostly at codons 12, 13 and 61 \[[@B6-ijms-17-02015]\]. The *BRAF^V600E^* mutation occurs in 10%--15% of mCRC \[[@B7-ijms-17-02015],[@B8-ijms-17-02015]\]. *BRAF^V600E^* mutant mCRC is associated with poorer outcomes. However, whether this mutation is predictive of resistance to anti-EGFR mAbs is uncertain \[[@B7-ijms-17-02015]\].

Only wild-type (WT) *RAS* mCRCs benefit from treatment with anti-EGFR mAbs. Nevertheless, nearly 35% of patients with WT *RAS* tumors do not respond to anti-EGFR treatment \[[@B3-ijms-17-02015],[@B4-ijms-17-02015],[@B6-ijms-17-02015]\]. Several molecular mechanisms underlying the development of treatment resistance have been reported in the literature \[[@B9-ijms-17-02015]\]. One possible explanation lies in tumor heterogeneity with regard to *RAS* mutations \[[@B8-ijms-17-02015],[@B10-ijms-17-02015]\]. There is a general consensus that progression of cancer develops from a single mutated cell, followed by clonal expansion associated with genetic alterations. The acquisition of these alterations can result in the emergence of new tumor subclones with different genotypes \[[@B11-ijms-17-02015]\]. Intra-tumoral heterogeneity is defined by the presence of at least two different tumoral subclones within the same tumor mass. Inter-tumoral heterogeneity consists in the presence of at least two different tumor subclones at different tumor sites in a single patient (i.e., primary tumor, metastatic lymph nodes or metastases) \[[@B12-ijms-17-02015]\]. Both intra- and inter-tumoral heterogeneity are important to identify since they could affect response to targeted therapies.

Different levels of tumoral heterogeneity have already been observed in several tumor types \[[@B13-ijms-17-02015],[@B14-ijms-17-02015],[@B15-ijms-17-02015]\]. Nevertheless, there are few data concerning intra- and inter-tumoral heterogeneity in CRC. *KRAS*, *NRAS* and *BRAF* mutations are considered to be mutually exclusive in CRC \[[@B16-ijms-17-02015]\]. Inter-tumoral heterogeneity seems to be relatively low between primary and metastatic lesions in mCRC since concordance of *KRAS* and *BRAF* status is over 95% \[[@B17-ijms-17-02015],[@B18-ijms-17-02015],[@B19-ijms-17-02015]\]. Nevertheless, these previous works used sequencing methods with low sensitivity and did not study complete *RAS* status. In addition, few data have been available concerning inter-tumoral heterogeneity of *RAS* and *BRAF* mutations between primary tumors and lymph node metastasis. Data concerning intra-tumoral heterogeneity of *RAS* and *BRAF* mutations between different areas of primary tumor data are lacking. In the present study, we investigated intra- and inter-tumoral heterogeneity of *RAS* and *BRAF* mutations in 60 tumor areas from 18 CRCs.

2. Results {#sec2-ijms-17-02015}
==========

2.1. Population {#sec2dot1-ijms-17-02015}
---------------

We retrospectively analyzed tumors from 18 patients with CRC (twelve colons and six rectums). Mean age at diagnosis was 66.5 ± 9.0 years ([Table 1](#ijms-17-02015-t001){ref-type="table"}). Tumor stages were stage I (*n* = 1, 5%), stage II (*n* = 3, 17%), stage III (*n* = 5, 28%) and stage IV (*n* = 9, 50%). According to the pathological tumor node metastasis (pTNM) staging, tumors were pT2 (*n* = 1, 5%), pT3 (*n* = 14, 78%) and pT4a (*n* = 3, 17%).

Tumors were assessed for *KRAS* mutations in codons 12 and 13 (*KRAS*^12−13^) on the initial transparietal section (ITS). Five tumors were *KRAS*^12−13^ mutant (MUT), seven tumors were *KRAS*^12−13^ WT and six tumors had potential low level (PLLM) *KRAS*^12−13^ mutations ([Table 2](#ijms-17-02015-t002){ref-type="table"}). Tumors with PLLM are defined as tumors with mutant allele frequency ≥limit of detection (LOD) and ≤LOD + 3% as described in the materials and methods section \[[@B8-ijms-17-02015]\]. One WT *KRAS* tumor had a *BRAF^V600E^* mutation.

2.2. Intra-Tumoral and Inter-Tumoral Heterogeneity of KRAS and NRAS Mutations {#sec2dot2-ijms-17-02015}
-----------------------------------------------------------------------------

Thirty-nine percent of mCRC studied harbored intra- and/or inter-tumoral heterogeneity ([Table 2](#ijms-17-02015-t002){ref-type="table"}).

Among the six tumors with intra-tumoral heterogeneity, only two were *KRAS*^12−13^ WT in ITS (cases 2 and 4). Three tumors (cases 2, 7, 12) presented *KRAS*^12−13^ PLLM or MUT in at least one of the tumor areas selected, but they also presented other *KRAS* or *NRAS* MUT or PLLM in other areas of the tumor (case 2) or in the same area (case 7, 12). An additional *NRAS*^117^ PLLM in the submucosa (pT1) was observed for one tumor (case 18) ([Table 2](#ijms-17-02015-t002){ref-type="table"} and [Figure S1](#app1-ijms-17-02015){ref-type="app"}). All in all, 33% of tumors (6/18) showed intra-tumoral heterogeneity for *RAS* mutation. The others presented either a WT pattern (cases 1, 3, 5, 6 and 10) or the same mutation with variation in allele frequency (cases 8, 11, 13--17) for all intra-tumoral areas ([Table 2](#ijms-17-02015-t002){ref-type="table"} and [Table S1](#app1-ijms-17-02015){ref-type="app"}).

To evaluate the inter-tumoral heterogeneity, we tested the metastatic lymph nodes and distant metastases for *KRAS*, *NRAS* and *BRAF* mutations when available. Among 11 cases analyzed, four presented inter-tumoral heterogeneity (36%). Three mutated primary tumors were WT in the metastatic lymph nodes (N+) or in the visceral metastases (M+) (cases 2, 12, 14) ([Table 2](#ijms-17-02015-t002){ref-type="table"}).

It is worth noting that all patients with mCRC with *RAS* PLLM and/or *RAS* mutation in a limited area of the tumor (i.e., intra- or inter-tumoral heterogeneity) treated with anti-EGFR mAbs had disease progression at 2--3 months (*n* = 5, cases 2, 7, 9, 11 and 12).

2.3. Mutational Intra-Tumoral Heterogeneity {#sec2dot3-ijms-17-02015}
-------------------------------------------

We focus on mutational intra-tumoral heterogeneity, defined as subclones with different mutant allele frequencies. Therefore, we calculated mutant allele frequency in neoplastic cells (MAFnc) and heterogeneity score (HS) for cases 7--9 and 13--18, which harbored the same mutation from the submucosa (pT1), the muscular layer (pT2) to the subserosa (pT3) ([Figure 1](#ijms-17-02015-f001){ref-type="fig"}). MAFnc is the mutant allele frequency normalized to 100% tumoral cells and HS corresponds to the fraction of neoplastic cells carrying a specific mutation and was calculated assuming that somatic mutations are usually heterozygous events \[[@B20-ijms-17-02015]\]. Mean HS increased with T stage, 128.4 ± 46.1 standard deviation (SD) in pT1, 234.1 ± 186.8 SD in pT2 and 296.2 ± 156.9 SD in pT3 (*p* = 0.03) ([Figure S2](#app1-ijms-17-02015){ref-type="app"}). We observed that HS was higher in pT3 areas in 55% of cases (*n* = 5/9) regardless of the mutation. Mean total HS (sum of HS for each mutation in one tumor) was 692.6 ± 262.6 SD. Total HS score was associated neither with tumor stage (*p* = 0.78), nor with tumor location (*p* = 0.90), nor with tumor recurrence (*p* = 0.56).

2.4. RAS Mutations Are Not Exclusive {#sec2dot4-ijms-17-02015}
------------------------------------

*RAS* mutations are considered to be mutually exclusive. Only a few articles have reported cases of coexisting *KRAS* and *NRAS* mutations \[[@B21-ijms-17-02015]\]. However, in our study, we observed that different *KRAS* mutations as well as *KRAS* and *NRAS* mutations may coexist. Five tumors had multiple *RAS* mutated subclones in the same tumor (28%). Moreover, four presented, in one of their tumor selections, at least two *RAS* mutated clones (22%) (cases 7, 9, 12, and 18) ([Table 2](#ijms-17-02015-t002){ref-type="table"}). Indeed, we observed the coexistence of different *KRAS* mutations in three tumors (17%) (cases 7, 9, 12) as well as *KRAS* and *NRAS* mutations in three tumors (17%) (cases 7, 9 and 18).

Tumors with two or more *RAS* mutations (cases 2, 7, 9, 12, and 18) as compared with tumors showing one *RAS* mutation (cases 8, 11, 13 to 17) were associated neither with tumor stage (*p* = 0.29) nor with tumor recurrence (*p* = 0.07).

3. Discussion {#sec3-ijms-17-02015}
=============

This study revealed a high proportion of intra- and inter-tumoral heterogeneity for *RAS* mutations in metastatic colorectal cancer. Nearly 40% of the mCRC studied harbored intra- and/or inter-tumoral heterogeneity. We also demonstrated the coexistence of different *RAS* mutations within the same tumor. These results have relevant clinical implications for anti-EGFR monoclonal antibodies prescription in mCRC since *RAS* mutations confer resistance to this treatment. Hence, testing of *KRAS* and *NRAS* mutations (codons 12, 13, 59, 61, 117 and 146) is a prerequisite for anti-EGFR mAbs used in mCRC. In daily practice, this testing usually relies on a single tumor sample with high tumor cell content. However, some patients with *RAS* WT tumor have primary resistance to anti-EGFR mAbs. One explanation is the limited sensitivity of testing methods, leading to false negative results \[[@B6-ijms-17-02015],[@B8-ijms-17-02015],[@B10-ijms-17-02015]\]. Nevertheless, intra- and/or inter-tumoral heterogeneity of *RAS* mutations could be the most important cause of therapeutic failure.

Indeed, recently, the "Big Bang" model emphasized that clonal alterations and subclonal events are an early event in CRC carcinogenesis with subclone mixing \[[@B22-ijms-17-02015]\]. Several neoplastic subclones with co-existing mutations in different genes (as well as different molecular alterations) could be present in a single primary tumor with different mutant allele frequencies \[[@B19-ijms-17-02015],[@B20-ijms-17-02015],[@B23-ijms-17-02015],[@B24-ijms-17-02015],[@B25-ijms-17-02015]\]. In our study, by testing *KRAS* and *NRAS* mutations in histologically relevant macrodissected zones according to pTNM, we observed the presence of (i) mutational intra-tumor heterogeneity with at least two co-existing *KRAS* and/or *NRAS* mutations within the same tumor areas and (ii) spatial intra-tumoral heterogeneity with coexistence within the same tumor of *KRAS* and/or *NRAS* mutated zones and WT zones. This intra-tumoral heterogeneity was found in 33% of cases in our study. Kosmidou et al. reported similar results (44%) of intra-tumoral heterogeneity for *KRAS* mutations when they compared tumor center and tumor periphery \[[@B23-ijms-17-02015]\]. Recently, Kim et al. observed a substantial level of intra-tumoral heterogeneity (46% to 80%) on multiregion biopsies from five mCRCs \[[@B26-ijms-17-02015]\]. Up until now, our study is one of the largest study concerning intra-tumoral heterogeneity and the only one concerning an extended *RAS* status.

*KRAS*, *NRAS* and *BRAF* mutations are considered to be mutually exclusive in CRC \[[@B16-ijms-17-02015]\]. Nevertheless, in our study, we observed the coexistence of two different *RAS* mutations in 28% of cases. We identified the coexistence of different *KRAS* mutations as well as *KRAS* and *NRAS* mutations. Coexistence of different *KRAS*^12−13^ mutations has been reported by others on small series \[[@B24-ijms-17-02015],[@B25-ijms-17-02015],[@B26-ijms-17-02015]\]. To our knowledge, the present study is one of the first reports concerning the coexistence of mutations in codons 12--13, 61 and 146 of *KRAS* (17% of cases). In addition, we demonstrated the coexistence of mutations in *KRAS* and *NRAS*, which has been reported only once in Vagaja, N.'s article \[[@B21-ijms-17-02015]\].

Concordance of *KRAS* and *BRAF* status between primary and metastatic lesions in mCRC has been considered to be over 95% \[[@B17-ijms-17-02015],[@B18-ijms-17-02015],[@B19-ijms-17-02015]\]. To our knowledge, few studies have evaluated inter-tumoral heterogeneity of *RAS* mutations between primary tumors and lymph nodes or distant metastatic lesions. We observed 36% of inter-tumoral heterogeneity, with *RAS* mutated primary tumors being WT in lymph nodes and/or distant metastatic lesions. In addition, metastatic lymph nodes may have different *RAS* mutations as compared to primary tumors. Concerning metastatic lymph nodes, only limited data concerning *KRAS* mutations are available. In one study, heterogeneity in *KRAS* mutations between primary tumors and lymph node metastases was found in approximately 30% of cases \[[@B27-ijms-17-02015]\]. To summarize, in some tumors, *KRAS* or *NRAS* mutations were "universal" as they were present in all macrodissected areas in primary lesions and in metastases. In other cases, we observed multiple subclones with mutations present only in one area or present in all areas in primary lesions but not in metastases, and they could be classified as "primary-private" and as "primary-clonal", respectively, as described by others \[[@B26-ijms-17-02015]\] ([Figure 2](#ijms-17-02015-f002){ref-type="fig"}).

In daily practice, *RAS* mutation testing is usually carried out on a single transparietal section of a given location with a high fraction of neoplastic cells. However, our results have shown that not all *RAS* mutations present in the tumor can be detected by the current sampling method. One alternative suggestion might be the preparation of a DNA mix obtained after macrodissection of multiple histologically relevant areas, as previously proposed \[[@B28-ijms-17-02015]\]. Moreover, for patients with multiple tumor biopsies and/or surgeries, it is important to perform *RAS* analyses on each sample. In addition, all *KRAS* and *NRAS* mutations must be sought simultaneously in first-line testing as they are not mutually exclusive.

All of these results concerning intra- and inter-tumoral heterogeneity are dependent on the sensitivity of the technique used. The more sensitive the sequencing technique, the higher the probability of detecting minority subclones when assessing intra- and inter-tumoral heterogeneity \[[@B8-ijms-17-02015],[@B10-ijms-17-02015],[@B29-ijms-17-02015]\]. However, the clinical relevance of these minority subclones called "potentially low-level mutants" is unknown (i.e., impact on anti-EGFR mAbs resistance). In a previous work, we demonstrated that low-frequency *KRAS* mutations (2.3% to 10%) are associated with resistance to anti-EGFR mAbs \[[@B8-ijms-17-02015]\]. More recently, Laurent-Puig et al., using highly sensitive picodroplet digital PCR (detection of one mutant *KRAS* allele in 200,000 WT *KRAS* alleles), suggested that patients with mCRC showing *KRAS*-mutated subclones lower or equal to 1% were benefiting from anti-EGFR therapies, while others were not (i.e., \>1%) \[[@B10-ijms-17-02015]\]. Due to the limited number of patients treated with anti-EGFR mAbs in our series, we cannot reliably assess the impact of intra- and inter-tumoral heterogeneity on anti-EGFR mAbs efficacy. Nevertheless, all patients with a mCRC harboring *RAS* PLLM and/or *RAS* mutations in a limited part of the tumor (i.e., intra- or inter-tumoral heterogeneity), and treated with anti-EGFR mAbs showed disease progression (*n* = 5). To conclude, *RAS* mutated subclones (\>1%) partially explain primary anti-EGFR mAbs resistance. In contrast, secondary resistances to anti-EGFR mAbs are partially due to *RAS* and *EGFR* mutation \[[@B30-ijms-17-02015],[@B31-ijms-17-02015],[@B32-ijms-17-02015]\].

One limitation of our study is the limited number of patients included, even though 78 samples from 18 tumors were analyzed. Moreover, in some cases, PPLM was found only in ITS but not in selected macrodissected areas in primary tumors. Interestingly, these results involved high tumoral cellularity cases, thereby confirming that the mutation is present but remains undetectable in the selected macrodissected areas. The major strengths of this study are: (1) analysis of extended *RAS* status; (2) multiple testing in primary tumors, metastatic lymph nodes and metastasis; and (3) use of a highly sensitive method.

With regard to tumor infiltration, the mutations were more frequently found in subserosa selections (pT3) and heterogeneity score increased with wall invasion; thus, pT3 selection seemed to be the best sampling zone for molecular analysis. In addition, we observed that HS was very high in several areas with a low fraction of neoplastic cells, thereby suggesting possible bias due to low tumoral cellularity or genomic amplification of the mutant allele or loss of the wild-type allele as well as mutation in both alleles \[[@B33-ijms-17-02015]\].

4. Materials and Methods {#sec4-ijms-17-02015}
========================

4.1. Tumor Samples {#sec4dot1-ijms-17-02015}
------------------

Tumoral zone selection was performed under HES (Haematoxylin-Erythrosin-Saffron) staining by two experienced pathologists (Marion Jeantet and Gaelle Fromont) according to the 2009 pTNM classification \[[@B34-ijms-17-02015]\]. For each tumor, selections involved the submucosa (pT1), the muscular layer (pT2), the subserosa (pT3), the metastatic lymph nodes (N+) and/or the visceral metastases (M+) when available. For instance, for a pT2 tumor, we performed pT1 and pT2 selections. For a pT3 or pT4 tumor, we performed pT1, pT2 and pT3 selections ([Figure 3](#ijms-17-02015-f003){ref-type="fig"}). The corresponding area of each tumoral zone selection was macrodissected and included in a new paraffin block. Another HES staining was performed to verify correspondence with the originally selected area. The percentage of tumor cells was assessed and selections with less than 5% of tumor cells were excluded.

A total of 60 tumoral macrodissections were analyzed. Among these samples, 15 were in pT1, 18 in pT2, 16 in pT3, 10 in N+ and 1 in M+. Four to six 10 µm thick sections were used for molecular analysis.

4.2. KRAS, NRAS and BRAF Mutation Testing {#sec4dot2-ijms-17-02015}
-----------------------------------------

Genomic DNA from macrodissected sections was extracted with the QIAamp DNA FFPE Tissue kit (Qiagen, Hilden, Germany). The 18 initial samples and the 60 newly macrodissected samples were tested for *KRAS* and *NRAS* mutations in codons 12--13 (*KRAS*^12−13^ and *NRAS*^12−13^), codon 59 (*KRAS*^59^ and *NRAS*^59^), codon 61 (*KRAS*^61^ and *NRAS*^61^), codon 117 (*KRAS*^117^ and *NRAS*^117^) and codon 146 (*KRAS*^146^ and *NRAS*^146^). *BRAF* was tested for mutation in codon 600 (*BRAF^V600E^*). Mutations were detected by pyrosequencing using TheraScreen *KRAS* PyroKit CE-IVD kit (Qiagen) for *KRAS*^12−13^ and *KRAS*^61^ or the PyroMark PCR kit (Qiagen) with homemade primers using PyroMark Assay Design 2.0 software (Qiagen, Hilden, Germany) for other *RAS* \[[@B35-ijms-17-02015]\] and *BRAF* mutations ([Table S2](#app1-ijms-17-02015){ref-type="app"}). PCR was carried out using 50 ng of DNA in a total volume of 25 µL according to the Qiagen supplier's instructions. Each series included a known-mutated and a known wild-type sample, as positive and negative controls. Pyrosequencing was performed using a Pyromark Q24 MDx according to the manufacturer's instructions (Qiagen).

4.3. Determination of Mutant Allele Burden and Tumoral Heterogeneity {#sec4dot3-ijms-17-02015}
--------------------------------------------------------------------

Mutant allele frequency was determined using PyroMark Q24 2.0.6 software (Qiagen). Limit of blank (LOB) and limit of detection (LOD) were considered during biological interpretation and all samples were analyzed with regard to the LOD, which was specific to each nucleotide position \[[@B35-ijms-17-02015]\]. Interpretation was carried out as follows: when the mutant allele frequency was \<LOD, the sample was considered as WT; when the mutant allele frequency was ≥LOD and ≤LOD + 3%, it was considered as PLLM and when the mutant allele frequency was \>LOD + 3%, it was considered as MUT. All mutations (PLLM and MUT) were confirmed at least twice, in two independent experiments.

Mutant allele frequency in neoplastic cells (MAFnc) and heterogeneity score (HS) were calculated as described in Normanno et al. \[[@B20-ijms-17-02015]\]. MAFnc is the mutant allele frequency normalized for the tumor cell content. Assuming that somatic mutations are usually heterozygous events, the HS was calculated by multiplying the frequency of mutant alleles in tumor cells by two. Therefore, HS virtually corresponds to the fraction of tumor cells carrying a specific mutation. HS \> 100 indicates a copy number variation, either a gain of mutant allele or a loss of WT allele.

4.4. Statistical Analyses {#sec4dot4-ijms-17-02015}
-------------------------

Differences in HS according to clinicopathological parameters were analyzed using the Mann--Whitney *U* test (comparison of two groups) or Kruskal--Wallis test (comparison of more than two groups). For dichotomous variables, Fisher\'s exact test was used. Statistical analyses were carried out with a two-sided test with a significance value of 0.05. All analyses were performed using Statview software (Statview for Windows, SAS Institute, version 5.0, Cary, NC, USA).

5. Conclusions {#sec5-ijms-17-02015}
==============

Concordance of *KRAS* and *BRAF* status between primary and metastatic lesions in mCRC has been considered to be over 95% \[[@B17-ijms-17-02015],[@B18-ijms-17-02015],[@B19-ijms-17-02015]\]. To our knowledge, the present study is one of the first reports concerning inter-tumoral heterogeneity of *RAS* mutations between primary tumors and lymph nodes or distant metastatic lesions. In conclusion, we have demonstrated the tumoral heterogeneity of *RAS* mutation and the co-existence of different *RAS* mutations in CRC, which may have major clinical implications. Our results question our daily practice and expose the limits of single transparietal sampling to ensure optimal molecular analysis. Macrodissection of multiple histologically relevant areas can be an interesting solution as proposed by Richman \[[@B28-ijms-17-02015]\]. The use of new sensitive new generation sequencing methods can also be an alternative option \[[@B36-ijms-17-02015]\]. However, the best solution may arise from peripheral blood testing since circulating tumor cells and circulating tumor DNA are the reflection of the whole tumor \[[@B37-ijms-17-02015],[@B38-ijms-17-02015]\]. These technologies provide another avenue to detect mutations, especially in patients with lymph nodes or distant metastasis.

Funding for this work was provided by the Ligue contre le Cancer of Vienne and of Deux-Sèvres, Poitou-Charentes region, Institut National du Cancer and the "Sport et Collection" and "Rotary Club de Civray" foundations. The authors wish to thank Jeffrey Arsham, an American translator, for having reviewed and revised the original English-language text. The authors thank Vanessa Le Berre, a research secretary, for her help in editing and formatting the manuscript.

Supplementary materials can be found at [www.mdpi.com/1422-0067/17/12/2015/s1](www.mdpi.com/1422-0067/17/12/2015/s1).

###### 

Click here for additional data file.

Lucie Karayan-Tapon, Gaelle Fromont, and David Tougeron conceived and designed the experiments; Marion Jeantet and Céline Archambaut performed the experiments; Marion Jeantet, Gaelle Tachon, and Lucie Karayan-Tapon analyzed the data; Ulrich Cortes and Gaelle Tachon contributed reagents/materials/analysis tools; Marion Jeantet, David Tougeron, Gaelle Tachon, and Lucie Karayan-Tapon wrote the paper.

The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

![Mutation allele frequency and heterogeneity score. Variability of mutation allele frequency and heterogeneity score between tumoral zone selections in cases which harbored the same mutation in pT1 to pT3. MAF: mutation allele frequency; HS: heterogeneity score.](ijms-17-02015-g001){#ijms-17-02015-f001}

![Subclone distribution in primary tumor and metastatic lymph node. In some cases, *KRAS* or *NRAS* mutations were universal/common as they were present in all macrodissected regions in primary tumors (PTs) and in metastatic lymph nodes (MLNs). In other cases, we observed multiple subclones with mutations present only in several regions but not all, or present in all regions in PT but not in MLN, and they could be classified as primary-clonal. In other cases, mutation was present only in one area of the tumor and could be classified as primary-private.](ijms-17-02015-g002){#ijms-17-02015-f002}

![Tumoral selection and macrodissection. (**A**) Tumoral selections on the HES slide: tumoral selections on the HES slide were performed according to pathological tumor node metastasis staging (pTNM) 2009 in submucosa (pT1), in the muscular layer (pT2) for pT2 tumors, selection in submucosa, in the muscular layer and in subserosa (pT3) for pT3 and pT4 tumors; (**B**) tumoral selections on the HES slide and paraffin block: tumoral zones selected on the HES slide were transposed on the corresponding paraffin block; and (**C**) paraffin blocks and HES slides of macrodissected tumoral selections: the corresponding area of each tumoral selection was macrodissected and included in a new paraffin block. An additional HES staining was performed to ensure correspondence with the originally selected area. ITS: initial transparietal section; HES: haematoxylin-erythrosin-saffron.](ijms-17-02015-g003){#ijms-17-02015-f003}

ijms-17-02015-t001_Table 1

###### 

Patients and tumor characteristics.

  Patient   Age    Sex   Tumor Site    Stage   pTNM 2009   Initial *KRAS*   Initial *BRAF*   Recurrence   OS      Status
  --------- ------ ----- ------------- ------- ----------- ---------------- ---------------- ------------ ------- --------
  2         77.9   F     right colon   III     pT3N1bM0    WT               WT               yes          48.68   dead
  3         75.9   M     left colon    III     pT4aN2bM0   WT               WT               no           2.50    alive
  4         79.2   F     right colon   II      pT3N0M0     WT               V600E            no           59.14   alive
  6         55.9   M     left colon    I       pT2N0M0     WT               WT               no           62.50   alive
  7         67.3   M     left colon    III     pT3N1bM0    G12S             WT               yes          69.21   dead
  8         72.9   F     left colon    IV      pT3N1bM1    G12V             WT               \-           26.35   dead
  9         58.5   M     left colon    III     pT4aN0M0    G12S             WT               yes          82.86   dead
  12        77.8   F     left colon    IV      pT4aN0M1    G12D             WT               \-           22.60   dead
  14        56.4   F     right colon   IV      pT3N1aM1    G12V             WT               \-           48.39   dead
  15        77.7   M     left colon    IV      pT3N2bM1    G12D             WT               \-           14.41   dead
  16        74.7   F     right colon   II      pT3N0M0     G12V             WT               no           37.70   alive
  13        66.0   M     left colon    II      pT3N0M0     G12V             WT               \-           49.00   alive
  1         61.9   M     rectum        IV      pT3N2bM1    WT               WT               \-           22.5    dead
  5         58.9   M     rectum        IV      pT3N0M1     WT               WT               \-           52.34   dead
  10        57.1   F     rectum        IV      pT3N2bM1    WT               WT               \-           44.80   dead
  11        65.2   F     rectum        IV      pT3N2bM1    G12D             WT               \-           17.96   dead
  17        54.9   F     rectum        III     pT3N2aM0    G12V             WT               yes          41.22   alive
  18        58.6   M     rectum        IV      pT3N0M1     G12R             WT               \-           43.82   dead

M: male; F: female; OS: overall survival; WT: wild-type; pTNM: pathological tumor node metastasis.

ijms-17-02015-t002_Table 2

###### 

*RAS* and *BRAF* mutations in the initial transparietal sections (*n* = 13) and spatially separated tumor areas (*n* = 43) in 13 colorectal cancers.

  Heterogeneity                                   Patients   pTNM                     %TC                       *KRAS*                       Other Genes
  ----------------------------------------------- ---------- ------------------------ ------------------------- ---------------------------- ---------------------
  Intra-tumoral heterogeneity                     4          ITS                      70                        WT                           *BRAF*:V600E (PLLM)
  pT1                                             30         WT                       WT                                                     
  pT2                                             90         WT                       *BRAF*:V600E (MUT)                                     
  9                                               ITS        70                       G12S (PLLM)/Q61R (PLLM)   *NRAS*:Q61R (MUT)            
  pT1                                             95         WT                       *NRAS*:Q61R (MUT)                                      
  pT2                                             70         WT                       *NRAS*:Q61R (MUT)                                      
  pT3                                             25         WT                       *NRAS*:Q61R (MUT)                                      
  18                                              ITS        80                       G12R (MUT)                WT                           
  pT1                                             30         G12R (MUT)               *NRAS* : K117N (PLLM)                                  
  pT2                                             35         G12R (MUT)               WT                                                     
  pT3                                             20         G12R (MUT)               WT                                                     
  Intra-tumoral and Inter-tumoral heterogeneity   2          ITS                      80                        WT                           *NRAS*: A59T (PLLM)
  pT2                                             15         WT                       WT                                                     
  pT3                                             20         G13D (MUT)               WT                                                     
  N                                               5          WT                       WT                                                     
  7                                               ITS        60                       G12S (PLLM)               FA (*NRAS*61 et *KRAS*146)   
  pT1                                             70         G12D (MUT)/Q61L (PLLM)   *NRAS*:Q61K (MUT)                                      
  pT2                                             25         G12S (MUT)               *NRAS*:Q61K (MUT)                                      
  pT3                                             40         Q61L (PLLM)              *NRAS*:Q61K (MUT)                                      
  N                                               25         WT                       *NRAS*:Q61K (MUT)                                      
  12                                              ITS        40                       G12D (PLLM)/A146T (MUT)   WT                           
  pT2                                             15         A146T (MUT)              WT                                                     
  pT3                                             20         Q61H(PLLM)/A146T (MUT)   FA (*BRAF*)                                            
  M                                               25         WT                       FA(*NRAS*59)                                           
  Inter-tumoral heterogeneity only                14         ITS                      30                        G12V (MUT)                   WT
  pT1                                             5          G12V (PLLM)              WT                                                     
  pT2                                             40         G12V (MUT)               WT                                                     
  pT3                                             5          G12V (PLLM)              WT                                                     
  N                                               5          WT                       WT                                                     
  Mutation without heterogeneity                  8          ITS                      30                        G12V (MUT)                   WT
  pT1                                             60         G12V (MUT)               WT                                                     
  pT2                                             75         G12V (MUT)               WT                                                     
  pT3                                             60         G12V (MUT)               WT                                                     
  N                                               80         G12V (MUT)               WT                                                     
  11                                              ITS        5                        G12D (PLLM)               WT                           
  pT2                                             5          G12D (MUT)               WT                                                     
  pT3                                             5          G12D (PLLM)              WT                                                     
  N                                               5          G12D (MUT)               WT                                                     
  13                                              ITS        70                       G12V (MUT)                WT                           
  pT1                                             70         G12V (MUT)               WT                                                     
  pT2                                             10         G12V (MUT)               WT                                                     
  pT3                                             15         G12V (MUT)               WT                                                     
  15                                              ITS        40                       G12D (MUT)                WT                           
  pT1                                             60         G12D (MUT)               WT                                                     
  pT2                                             15         G12D (MUT)               WT                                                     
  pT3                                             20         G12D (MUT)               WT                                                     
  N                                               40         G12D (MUT)               WT                                                     
  16                                              ITS        40                       G12V (MUT)                WT                           
  pT1                                             80         G12V (MUT)               WT                                                     
  pT2                                             40         G12V (MUT)               WT                                                     
  pT3                                             10         G12V (MUT)               WT                                                     
  17                                              ITS        30                       G12V (MUT)                WT                           
  pT1                                             30         G12V (MUT)               WT                                                     
  pT2                                             20         G12V (MUT)               WT                                                     
  pT3                                             10         G12V (MUT)               WT                                                     
  N                                               20         G12V (MUT)               WT                                                     

%TC: percentage of tumoral cells; ITS: initial transparietal section; N: metastatic lymph node; M: metastasis; WT: wild-type; PLLM: potential low level mutation; MUT: mutant; FA: failed analysis.
